A small single-arm trial of patients with low-risk (no B symptoms or extranodal disease and limited sites of recurrence), relapsed, classic Hodgkin lymphoma (n=28) demonstrates a 95% progression-free survival rate with salvage response-adapted chemoimmunotherapy followed by consolidative involved site radiation in lieu of stem cell transplant. | Hoppe, ASTRO 2023
